Management of glioma in Victoria (1998-2000): Retrospective cohort study

Medical Journal of Australia

Volumn 184, Issue 6, 2006, Pages 270-273

  Rosenthal, Mark A ^a   Drummond, Katharine J ^a   Dally, Michael ^b   Murphy, Michael ^c   Cher, Lawrence ^d   Ashley, David ^e   Thursfield, Vicky ^f   Giles, Graham G ^f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d AUSTIN HEALTH   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GLIOMA; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OVERALL SURVIVAL; PATIENT CARE; REGISTER; RETROSPECTIVE STUDY; STANDARD; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY;

EID: 33645465161     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00235.x     Document Type: Article

References (16)

1. Thursfield V, Farrugia H, Billiet D, Giles G, editors. Cancer in Victoria 2003. Melbourne: The Cancer Council Victoria, 2004. (Canstat Series No. 41.)
2. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-468.
3. Lacroix M, Abi-Said D, Fourney D, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
4. Sawaya R. Extent of resection in malignant glioma: a critical summary. J Neurooncol 1999; 42: 303-305.
5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 2005. Available at: http://www.nccn.org/professionals/physician_gls/default.asp (accessed Feb 2006).
6. Stupp R, Pavlidis N, Jelic S; European Society of Medical Oncology Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 2005; 16 Supp I: i64-i65.
7. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557-564.
8. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
9. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Gliomas Outcome Project. Neurosurgery 2004; 54: 358-366.
10. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64: 259-273.
11. Chang SM, Barker FG, Schmidt MH, et al. Clinical trial participation among patients enrolled in the Glioma Outcomes Project. Cancer 2002; 94: 2681-2687.
12. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on re-growth and prognosis. Neurosurgery 1994; 34; 45-61.
13. Harris MT, Rosenthal MA, Ashley DL, Cher L. An Australian experience with temozolomide for the treatment of recurrent high-grade gliomas. J Clin Neurosci 2001; 8: 325-327.
14. Yung KA, Albright R, Olson J, et al. A phase II study of temozolomide vs procarbazine in glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
15. MacDonald DR, Kiebert G, Prados M, Yung A, Olson J. Benefit of temozolomide compared with procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest 2005; 23: 138-144.
16. Stupp R, Mason WP, van den Bent ML, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.